预测吉兰-巴雷综合征的结局:改良Erasmus GBS结局评分的国际验证
研究利用国际GBS结局研究(IGOS)中1500例年龄≥6岁且不能独立行走的患者前瞻性数据,验证改良Erasmus GBS结局评分(mEGOS)在入组时和1周时预测4周和26周不能独立行走的能力。结果显示各区域亚组AUC均>0.7,欧洲/北美观察结局差于预测,亚洲观察结局优于预测,重新校准后开发了欧洲/北美区域特异性版本(mEGOS-Eu/NA)。
要点
- mEGOS在外部国际队列中验证可预测GBS患者4周和26周不能独立行走。
- 各区域亚组AUC值均>0.7,但欧洲/北美观察结局差于预测,亚洲优于预测。
- 重新校准后开发了欧洲/北美区域特异性版本mEGOS-Eu/NA。
核心结论
- mEGOS是经过验证的工具,可预测GBS患者在4周和26周时不能独立行走,在荷兰以外的国家也适用。
- 我们为欧洲/北美患者开发了mEGOS的区域特异性版本。
研究设计与样本
- 研究使用国际GBS结局研究(IGOS)中前1500例入组患者的前瞻性数据,患者年龄≥6岁且不能独立行走。
- 评估入组时和1周时mEGOS预测4周和26周不能独立行走的能力,采用AUC评估区分度、观察概率与预测概率评估校准度。
- 对包含总体mEGOS评分的模型进行重新校准,不改变个体预测因子,并评估个体预测因子的预测能力。
主要发现
- 验证入组时mEGOS合格患者809例(欧洲/北美677例,亚洲76例,其他56例),验证1周时mEGOS合格患者671例(欧洲/北美563例,亚洲65例,其他43例)。
- 所有区域亚组的AUC值均>0.7。
- 欧洲/北美亚组观察结局差于预测,亚洲观察结局优于预测。
- 重新校准提高了模型准确性,并开发了欧洲/北美区域特异性版本mEGOS-Eu/NA。
- 与原始mEGOS相似,严重肢体无力和较高年龄是IGOS队列中不良结局的主要预测因子。
关键数值与推荐
- mEGOS在入组时和1周时预测4周和26周不能独立行走,各区域亚组AUC值均>0.7。
- 本研究提供Class II证据,表明mEGOS能准确预测GBS患者4周和26周不能独立行走。
临床怎么用
- mEGOS可用于预测GBS患者4周和26周不能独立行走的风险,在荷兰以外国家也适用。
- 对于欧洲/北美患者,可使用区域特异性版本mEGOS-Eu/NA进行预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The clinical course and outcome of the Guillain-Barré syndrome (GBS) are diverse and vary among regions. The modified Erasmus GBS Outcome Score (mEGOS), developed with data from Dutch patients, is a clinical model that predicts the risk of walking inability in patients with GBS. The study objective was to validate the mEGOS in the International GBS Outcome Study (IGOS) cohort and to improve its performance and region specificity. METHODS: We used prospective data from the first 1,500 patients included in IGOS, aged ≥6 years and unable to walk independently. We evaluated whether the mEGOS at entry and week 1 could predict the inability to walk unaided at 4 and 26 weeks in the full cohort and in regional subgroups, using 2 measures for model performance: (1) discrimination: area under the receiver operating characteristic curve (AUC) and (2) calibration: observed vs predicted probability of being unable to walk independently. To improve the model predictions, we recalibrated the model containing the overall mEGOS score, without changing the individual predictive factors. Finally, we assessed the predictive ability of the individual factors. RESULTS: For validation of mEGOS at entry, 809 patients were eligible (Europe/North America [n = 677], Asia [n = 76], other [n = 56]), and 671 for validation of mEGOS at week 1 (Europe/North America [n = 563], Asia [n = 65], other [n = 43]). AUC values were >0.7 in all regional subgroups. In the Europe/North America subgroup, observed outcomes were worse than predicted; in Asia, observed outcomes were better than predicted. Recalibration improved model accuracy and enabled the development of a region-specific version for Europe/North America (mEGOS-Eu/NA). Similar to the original mEGOS, severe limb weakness and higher age were the predominant predictors of poor outcome in the IGOS cohort. DISCUSSION: mEGOS is a validated tool to predict the inability to walk unaided at 4 and 26 weeks in patients with GBS, also in countries outside the Netherlands. We developed a region-specific version of mEGOS for patients from Europe/North America. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the mEGOS accurately predicts the inability to walk unaided at 4 and 26 weeks in patients with GBS. TRIAL REGISTRATION INFORMATION: NCT01582763.
引用
- Doets AY, Lingsma HF, Walgaard C, et al. Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score. Neurology. 2021. PMID: 34937789. doi:10.1212/WNL.0000000000013139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。